List view / Grid view
28 September 2016 | By Niamh Louise Marriott, Digital Content Producer
For the treatment of pancreatic cancer, EryTech are now looking to develop 'tumour starvation' treatments for acute leukaemia and have enrolled their...
25 July 2016 | By Niamh Louise Marriott, Digital Content Producer
The positive opinion is based on a pivotal Phase 3 study showing that Onivyde combined with chemotherapy significantly increased overall survival in patients with metastatic pancreatic cancer...
29 March 2016 | By Victoria White
The ARCHES trial will evaluate the efficacy and safety of enzalutamide with androgen deprivation therapy (ADT) versus placebo with ADT in mHSPC patients...
21 March 2016 | By Victoria White
Professor Paul Workman of The Institute of Cancer Research, which discovered abiraterone, said the recommendation was “a big victory for men"...
17 March 2016 | By Victoria White
The trial will study PEGPH20 in combination with nab-paclitaxel and gemcitabine in patients with tumours that accumulate high levels of hyaluronan...
14 March 2016 | By Victoria White
In a study, abiraterone acetate plus prednisone provided an 11.8 months overall survival benefit compared to an active control of placebo plus prednisone...
29 February 2016 | By Victoria White
Celgene has announced that that of the Health Service Executive (HSE) of Ireland has recommended two cancer treatments: Imnovid and Abraxane...
11 February 2016 | By Victoria White
Incyte has decided to discontinue the Phase 3 JANUS 1 study of ruxolitinib or placebo in combination with capecitabine for the second-line treatment of patients with advanced or metastatic pancreatic cancer.
8 February 2016 | By Victoria White
The research collaboration will test RP101 in preclinical oncology models in combination with standard-of-care chemotherapies to support existing Phase I and Phase II clinical data...
28 January 2016 | By Victoria White
This Lynparza BTD is for the treatment of BRCA1/2 or ATM gene mutated metastatic Castration Resistant Prostate Cancer...
27 January 2016 | By Victoria White
The study achieved its primary endpoint demonstrating a statistically significant increase in PFS for enzalutamide compared with bicalutamide...
25 January 2016 | By Victoria White
Celgene has announced results from multiple analyses evaluating second-line treatments following Abraxane and gemcitabine (AG) in metastatic pancreatic cancer patients.
14 January 2016 | By
The TERRAIN study achieved its primary endpoint demonstrating a statistically significant increase in progression-free survival for enzalutamide compared to bicalutamide...
6 January 2016 | By Victoria White
The Phase 1 study, initiated by Washington University, will evaluate VS-6063 in combination with pembrolizumab and gemcitabine in patients with pancreatic cancer...
11 December 2015 | By Victoria White
The National Institute for Health and Care Excellence (NICE) has published draft guidance on two prostate cancer treatments - enzalutamide and abiraterone...
